Casma Therapeutics

OverviewSuggest Edit

Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines. The Company uses several approaches to intervene at strategic points throughout the autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens and to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders, and neurodegeneration, among other indications.

TypePrivate
Founded2018
HQCambridge, MA, US
Websitecasmatx.com

Latest Updates

Employees (est.) (Dec 2020)46
Cybersecurity ratingBMore

Key People/Management at Casma Therapeutics

Keith Dionne

Keith Dionne

Chief Executive Officer, Director
Frank Gentile

Frank Gentile

Chief Operating Officer
Leon Murphy

Leon Murphy

Chief Scientific Officer
Jeff Saunders

Jeff Saunders

Sr. Vice President of Drug Discovery
Caren Block

Caren Block

Vice President of People & Culture
Daniel Ory

Daniel Ory

Sr. Vice President of Translational Medicine
Show more

Casma Therapeutics Office Locations

Casma Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
400 Technology Square, 400 Technology Square
Show all (1)

Casma Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2018

Casma Therapeutics total Funding

$108.5 m

Casma Therapeutics latest funding size

$50 m

Time since last funding

3 months ago

Casma Therapeutics investors

Casma Therapeutics's latest funding round in September 2020 was reported to be $50 m. In total, Casma Therapeutics has raised $108.5 m
Show all financial metrics

Casma Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Casma Therapeutics Online and Social Media Presence

Embed Graph

Casma Therapeutics Blogs

Casma Therapeutics and Vipergen Enter Into Drug Discovery Agreement

CAMBRIDGE, Mass. & COPENHAGEN, Denmark- December 1, 2020-Casma Therapeutics, Inc. and Vipergen ApS announced today the signing of a drug discovery agreement. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library (DEL) technology platform to disco…

Casma Therapeutics Appoints Nagesh Mahanthappa, Ph.D., MBA, to Board of Directors

CAMBRIDGE, Mass.-November 17, 2020 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointment of Nagesh Mahanthappa, Ph.D., MBA, to its Board of Directors. “We are pleased to welcome Nagesh to our Board of…

Casma Therapeutics Announces $50 Million Series B Financing

Funding led by The Column Group Proceeds will be used to advance Casma’s First-in-Class TRPML1 agonist in muscular dystrophy and enable preclinical proof-of-concept for the Company’s novel autophagy degrader platform CAMBRIDGE, Mass.-September 10, 2020-(BUSINESS WIRE)–Casma Therapeutics, Inc., a bio…

Casma Therapeutics Appoints Two Experts in Lysosomal Proteostasis Pathways and Functional Genomics to Scientific Advisory Board

CAMBRIDGE, Mass.- January 13, 2020 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Christian Grimm, Ph.D., and Martin Kampmann, Ph.D., will join its scientific advisory board. “Christian and Martin are at …

Casma Therapeutics Appoints Renowned Proteomic Specialist Steven Gygi to Scientific Advisory Board

CAMBRIDGE, Mass. – October 16, 2019 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Steven Gygi, Ph.D., will join its scientific advisory board. A professor of cell biology at Harvard Medical School, Gygi …

Casma Therapeutics Named a 2019 “Fierce 15” Biotech Company

CAMBRIDGE, Mass., September 23, 2019 — Casma Therapeutics today announced that it has been named to the 2019 Fierce 15 list by FierceBiotech for its pioneering work to harness the potential of autophagy to design powerful new medicines. The award honors the most promising private biotechnology compa…

Casma Therapeutics Frequently Asked Questions

  • When was Casma Therapeutics founded?

    Casma Therapeutics was founded in 2018.

  • Who are Casma Therapeutics key executives?

    Casma Therapeutics's key executives are Keith Dionne, Frank Gentile and Leon Murphy.

  • How many employees does Casma Therapeutics have?

    Casma Therapeutics has 46 employees.

  • Who are Casma Therapeutics competitors?

    Competitors of Casma Therapeutics include AOBiome, Rallybio and NantKwest.

  • Where is Casma Therapeutics headquarters?

    Casma Therapeutics headquarters is located at 400 Technology Square, 400 Technology Square, Cambridge.

  • Where are Casma Therapeutics offices?

    Casma Therapeutics has an office in Cambridge.

  • How many offices does Casma Therapeutics have?

    Casma Therapeutics has 1 office.